Skip to main content

Table 1 Basic patient and tumor characteristics.

From: The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial

 

E-T-CMF

E-CMF

All patients

Number

141

167

308

Age (years)

   

   Median

50

50

50

   Range

24 to 76

22 to 78

22 to 78

Number of nodes removed

   

   Median

19

20

20

   Range

5 to 59

4 to 53

4 to 59

Number of positive nodes

   

   Median

7

6

6

   Range

0 to 54

0 to 49

0 to 54

 

N

%

N

%

N

%

   0 to 3 nodes

30

21.3

45

26.9

75

24.4

   ≥4

111

78.7

122

73.1

233

75.6

Menopausal status

      

   Premenopausal

76

53.9

89

53.3

165

53.6

   Postmenopausal

65

46.1

78

46.7

143

46.4

Type of operation

      

   Modified radical mastectomy

111

78.7

132

79.0

243

78.9

   Breast conserving surgery

30

21.3

35

21.0

65

21.1

Interval from operation

      

   <2 weeks

17

12.1

24

14.4

41

13.3

   2 to 4 weeks

72

51.1

70

41.9

142

46.1

   >4 weeks

52

36.9

73

43.7

125

40.6

Tumor size

      

   ≤2cm

40

28.4

52

31.1

92

29.9

   2 to 5cm

79

56.0

83

49.7

162

52.6

   >5cm

22

15.6

32

19.2

54

17.5

Histological gradea

      

   I-II

60

42.6

97

58.1

157

51.0

   III-IV

81

57.4

70

41.9

151

49.0

ER/PgR status

      

   Negative

28

19.9

29

17.4

57

18.5

   Positive

95

67.4

108

64.7

203

65.9

   Missing data

18

12.8

30

18.0

48

15.6

HER2 statusb

      

   Negative

79

56.0

100

59.9

179

58.1

   Positive

35

24.8

32

19.2

67

21.8

   Missing data

27

19.1

35

21.0

62

20.1

Adjuvant RT

      

   No

21

14.9

33

19.8

54

17.5

   Yes

119

84.4

133

79.6

252

81.8

   Missing data

1

0.7

1

0.6

2

0.6

Adjuvant HT

      

   No

8

5.7

18

10.8

26

8.4

   Yes

133

94.3

149

89.2

282

91.6

   Tamoxifen

120

85.1

127

76.0

247

80.2

   LH-RH agonist

65

46.1

62

37.1

127

41.2

   Aromatase inhibitors

5

3.5

6

3.6

11

3.6

   Other

1

0.7

2

1.2

3

1.0

  1. aThe two treatment arms were not balanced in terms of histological grade (P = 0.008); bpositive HER2 status: HER2 3+ by IHC and/or HER2 amplification by FISH. CMF, cyclophosphamide, methotrexate, fluorouracil; ER, estrogen receptor; FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; HT, hormonal therapy; IHC, immunohistochemistry; LH-RH, luteinizing hormone-releasing hormone; PgR, progesterone receptor; RT, radiation therapy.